KPG-818

DRUG2 trials

Sponsors

Kangpu Biopharmaceuticals, Ltd.

Conditions

Hematological MalignanciesSystemic Lupus Erythematosus

Phase 1

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

CompletedNCT03949426

Kangpu Biopharmaceuticals, Ltd.Systemic Lupus Erythematosus

Start: 2019-05-01End: 2019-09-29Updated: 2020-02-25

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

CompletedNCT04283097

Kangpu Biopharmaceuticals, Ltd.Hematological Malignancies

Start: 2021-09-13End: 2024-12-12Updated: 2025-05-16

Related Papers

Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study

Blood2025-11-03